Cargando…

Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment

There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiaoli, Li, Hualan, Liu, Zhihui, Liao, Sina, Li, Qian, Liang, Chaoyong, Huang, Yu, Xie, Mingzhi, Wei, Junbao, Li, Yongqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320137/
https://www.ncbi.nlm.nih.gov/pubmed/30558053
http://dx.doi.org/10.1097/MD.0000000000013635
_version_ 1783385179554840576
author Liao, Xiaoli
Li, Hualan
Liu, Zhihui
Liao, Sina
Li, Qian
Liang, Chaoyong
Huang, Yu
Xie, Mingzhi
Wei, Junbao
Li, Yongqiang
author_facet Liao, Xiaoli
Li, Hualan
Liu, Zhihui
Liao, Sina
Li, Qian
Liang, Chaoyong
Huang, Yu
Xie, Mingzhi
Wei, Junbao
Li, Yongqiang
author_sort Liao, Xiaoli
collection PubMed
description There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed. Twenty seven patients with advanced colorectal cancer who had failed at least 2 lines chemotherapy were treated with apatinib (500 mg/day). As a comparison control, 26 advanced colorectal cancer patients with comparable clinical baseline characteristics including age, sex, Eastern Cooperative Oncology Group (ECOG) score, pathological type, carcinoembryonic antigen (CEA) level, tumor location, number and location(s) of metastasis, and previous chemotherapies were subject to observation. Survival analyses were performed via the Kaplan–Meier method. The toxicity were evaluated in all patients this study according to the National Cancer Institute Common Toxicity Criteria 4 (NCI CTC version 4.0). A total of 53 well-matched patients with advanced colorectal cancer were retrospectively analyzed. The median follow-up time was 6.0 months (2.0–16.0 months). The median PFS was significantly longer for apatinib group than for observation group (2.0 vs. 1.1 months; HR = 3.88; 95% confidence interval [CI], 1.91–7.88; P < .001). However, there was no significant difference between the 2 groups for median OS (5.0 vs. 4.0 months; HR = 1.03; 95% CI, 0.56–1.90; P = .914). The disease control rate of the apatinib group was significantly better than that of the observation group (70.4% vs 26.9%, P = .002). There was no significant difference in the overall remission rate between the 2 groups (3.7% vs 0%, P = .322). Advanced colorectal cancer patients with 2 or fewer metastatic sites experienced longer PFS than those with more than 2 sites. High ECOG scores, cancer localization to the right side of colon and lymph node metastasis were associated with increased risk of death and all remained independent factors affecting OS. The most common grade 3/4 treatment-related adverse events were hypertension and hand-foot skin syndrome. Apatinib treatment for patients with advanced colorectal cancer who had failed chemotherapy achieved better disease control and prolonged PFS relative to untreated controls. The toxicity was manageable.
format Online
Article
Text
id pubmed-6320137
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63201372019-01-14 Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment Liao, Xiaoli Li, Hualan Liu, Zhihui Liao, Sina Li, Qian Liang, Chaoyong Huang, Yu Xie, Mingzhi Wei, Junbao Li, Yongqiang Medicine (Baltimore) Research Article There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed. Twenty seven patients with advanced colorectal cancer who had failed at least 2 lines chemotherapy were treated with apatinib (500 mg/day). As a comparison control, 26 advanced colorectal cancer patients with comparable clinical baseline characteristics including age, sex, Eastern Cooperative Oncology Group (ECOG) score, pathological type, carcinoembryonic antigen (CEA) level, tumor location, number and location(s) of metastasis, and previous chemotherapies were subject to observation. Survival analyses were performed via the Kaplan–Meier method. The toxicity were evaluated in all patients this study according to the National Cancer Institute Common Toxicity Criteria 4 (NCI CTC version 4.0). A total of 53 well-matched patients with advanced colorectal cancer were retrospectively analyzed. The median follow-up time was 6.0 months (2.0–16.0 months). The median PFS was significantly longer for apatinib group than for observation group (2.0 vs. 1.1 months; HR = 3.88; 95% confidence interval [CI], 1.91–7.88; P < .001). However, there was no significant difference between the 2 groups for median OS (5.0 vs. 4.0 months; HR = 1.03; 95% CI, 0.56–1.90; P = .914). The disease control rate of the apatinib group was significantly better than that of the observation group (70.4% vs 26.9%, P = .002). There was no significant difference in the overall remission rate between the 2 groups (3.7% vs 0%, P = .322). Advanced colorectal cancer patients with 2 or fewer metastatic sites experienced longer PFS than those with more than 2 sites. High ECOG scores, cancer localization to the right side of colon and lymph node metastasis were associated with increased risk of death and all remained independent factors affecting OS. The most common grade 3/4 treatment-related adverse events were hypertension and hand-foot skin syndrome. Apatinib treatment for patients with advanced colorectal cancer who had failed chemotherapy achieved better disease control and prolonged PFS relative to untreated controls. The toxicity was manageable. Wolters Kluwer Health 2018-12-14 /pmc/articles/PMC6320137/ /pubmed/30558053 http://dx.doi.org/10.1097/MD.0000000000013635 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Liao, Xiaoli
Li, Hualan
Liu, Zhihui
Liao, Sina
Li, Qian
Liang, Chaoyong
Huang, Yu
Xie, Mingzhi
Wei, Junbao
Li, Yongqiang
Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title_full Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title_fullStr Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title_full_unstemmed Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title_short Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
title_sort clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320137/
https://www.ncbi.nlm.nih.gov/pubmed/30558053
http://dx.doi.org/10.1097/MD.0000000000013635
work_keys_str_mv AT liaoxiaoli clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT lihualan clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT liuzhihui clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT liaosina clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT liqian clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT liangchaoyong clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT huangyu clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT xiemingzhi clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT weijunbao clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment
AT liyongqiang clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment